Fesko John sold $2.1M of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 6,517 shares of Natera, Inc. (NTRA) at $321.53 ($2.10M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Aug 29, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale may influence short‑term sentiment but the company’s fundamentals remain unchanged.

02

Market read

First‑hand insider sale provides fresh data for traders monitoring NTRA.

03

What to watch

The insider retains a large stake (197,257 shares) indicating continued commitment.

Relevance 5/10Novelty 8/10Timing: after‑hours filing on 2026‑08‑28

Background

SEC Form 4 filing discloses an insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President and COO John Fesko sold 6,517 Natera shares for $2.1M via a 10b5‑1 plan.

Expected impact

Potential short‑term downside pressure, 1‑2% dip if market reacts.

Evidence & confidence

Sale size is modest but the insider is a senior officer; 10b5‑1 plans soften the signal but still warrant caution.

Market effects

May raise concerns for other reproductive‑health biotech stocks.

Limited to US biotech sector.

Minimal global effect.

Counterpoint

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a lack of confidence.

Key entities

  • Natera, Inc.

    US‑listed genetic testing company (ticker NTRA).

  • John Fesko

    President and Chief Business Officer of Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.